Posted by Michael Wonder on 04 May 2022
Pliant Therapeutics receives FDA fast track designation for PLN-74809 for the treatment of idiopathic pulmonary fibrosis
3 May 2022 - Pliant Therapeutics announced today that PLN-74809, its oral, dual-selective αvß6/αvß1 integrin inhibitor, has received fast track designation from the U.S. FDA for the potential treatment of idiopathic pulmonary fibrosis.
PLN-74809, the Company’s lead drug candidate, is currently being tested as part of the INTEGRIS-IPF Phase 2a clinical trial.
